Polar Capital Holdings Plc Invests $38.40 Million in Zenas BioPharma, Inc. $ZBIO

Polar Capital Holdings Plc acquired a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,057,609 shares of the company’s stock, valued at approximately $38,402,000.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after acquiring an additional 290,307 shares during the period. NEXTBio Capital Management LP acquired a new position in shares of Zenas BioPharma in the fourth quarter valued at about $11,691,000. UBS Group AG raised its stake in shares of Zenas BioPharma by 95.8% in the fourth quarter. UBS Group AG now owns 69,495 shares of the company’s stock worth $2,523,000 after purchasing an additional 34,003 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Zenas BioPharma in the fourth quarter worth about $211,000. Finally, Marshall Wace LLP acquired a new stake in shares of Zenas BioPharma during the fourth quarter worth about $258,000.

Analyst Upgrades and Downgrades

ZBIO has been the topic of several research reports. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Guggenheim raised their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Morgan Stanley boosted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Insider Activity at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were purchased at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hongbo Lu purchased 3,768 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were purchased at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the transaction, the director owned 426,736 shares of the company’s stock, valued at $7,950,091.68. This trade represents a 0.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 273,768 shares of company stock worth $5,150,198 in the last three months. Company insiders own 22.00% of the company’s stock.

Zenas BioPharma Trading Down 2.8%

Shares of NASDAQ:ZBIO opened at $18.19 on Wednesday. Zenas BioPharma, Inc. has a 12-month low of $8.91 and a 12-month high of $44.60. The company has a market capitalization of $1.15 billion, a PE ratio of -2.15 and a beta of -0.71. The business has a 50 day moving average of $19.32 and a two-hundred day moving average of $24.27. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same period in the previous year, the business posted ($0.80) earnings per share. As a group, analysts forecast that Zenas BioPharma, Inc. will post -4.47 EPS for the current year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.